ARCHIVES

Biotherapeutics Reports LAK/IL-2 Toxicity Reduced With Constant Infusion Of IL-2

This article is from The Cancer Letter archive.

Vol. 13 No. 16 | April 17, 1987

Download PDF Visit The Full Archive

Related Articles

In Brief: Durant Says He Expects Comprehensive Centers Lineup to Change With New System

December 15, 1989

BMS Agent Yervoy Received FDA Approval for Metastatic Melanoma

March 25, 2011

State Cancer Incidence Report Published by NCI, CDC

November 22, 2002

LabCorp Marketing Of Ovarian Cancer Test Unlawful, FDA Says In Warning Letter.

October 17, 2008

DCPC Advisors Commit $32 Mil. To Chemoprevention

June 7, 1991

Six Centers Win Grants

July 11, 2003